A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor ( EGFR ) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study.

Autor: Mountzios G; Fourth Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, 11526 Athens, Greece., Koumarianou A; Hematology-Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece., Bokas A; First Department of Clinical Oncology, Theagenio Cancer Hospital, 54007 Thessaloniki, Greece., Mavroudis D; Department of Medical Oncology, University Hospital of Heraklion, 71110 Crete, Greece., Samantas E; 2nd Oncology Department, Metropolitan Hospital, 18547 Athens, Greece., Fergadis EG; Medical Oncology Department, Metaxa Cancer Hospital, 18537 Piraeus, Greece., Linardou H; 4th Oncology Department & Comprehensive Clinical Trials Center, Metropolitan Hospital, 18547 Athens, Greece., Katsaounis P; Oncology Department, Metropolitan Hospital, 15562 Athens, Greece., Athanasiadis E; Department of Medical Oncology, Mitera Hospital, 15123 Athens, Greece., Karamouzis MV; Molecular Oncology Unit, Department of Biological Chemistry Medical School, 11525 Athens, Greece., Pentheroudakis G; Department of Medical Oncology, Medical School University of Ioannina, 45500 Ioannina, Greece., Lampaki S; Pulmonary Department, General Hospital 'G. Papanikolaou', Aristotle University of Thessaloniki, 57010 Thessaloniki, Greece., Froudarakis ME; Department of Respiratory Medicine, Medical School of Alexandroupolis Democritus University of Thrace, 68100 Alexandroupolis, Greece., Perdikouri EA; Oncology Department, General Hospital 'Papageorgiou', Aristotle University of Thessaloniki, 56429 Thessaloniki, Greece., Somarakis A; Medical Affairs Department, AstraZeneca, 15123 Athens, Greece., Papageorgiou F; Diagnostics Function Oncology, AstraZeneca, 15123 Athens, Greece., Paparepa Z; Clinical Operations, AstraZeneca, 15123 Athens, Greece., Nikolaou A; Medical Affairs Department, AstraZeneca, 15123 Athens, Greece., Syrigos KN; Third Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria Hospital, 11527 Athens, Greece.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2021 Jun 25; Vol. 13 (13). Date of Electronic Publication: 2021 Jun 25.
DOI: 10.3390/cancers13133172
Abstrakt: Background : Real-world data on the molecular epidemiology of EGFR resistance mutations at or after progression with first- or second-generation EGFR-TKIs in patients with advanced NSCLC are lacking. Methods : This ongoing observational study was carried out by 23 hospital-based physicians in Greece. The decision to perform cobas ® EGFR Mutation Test v2 in tissue and/or plasma at disease progression was made before enrollment. For patients with negative/inconclusive T790M plasma-based results, tissue re-biopsy could be performed. Results : Ninety-six (96) eligible patients were consecutively enrolled (median age: 67.8 years) between July-2017 and September-2019. Of the patients, 98% were tested upon progression using plasma and 2% using tissue/cytology biopsy. The T790M mutation was detected in 16.0% of liquid biopsies. Tissue re-biopsy was performed in 22.8% of patients with a T790M-negative plasma result. In total, the T790M positivity rate was 21.9%, not differing between patients on first- or second-generation EGFR-TKI. Higher (≥2) ECOG performance status and longer (≥10 months) time to disease progression following EGFR-TKI treatment initiation were associated with T790M positivity. Conclusions : Results from plasma/tissue-cytology samples in a real-world setting, yielded a T790M positivity rate lower than previous reports. Fewer than one in four patients with negative plasma-based testing underwent tissue re-biopsy, indicating the challenges in routine care settings.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje